Crossmark

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Crossref DOI link: https://doi.org/10.1016/S2213-2600(21)00160-0

Published Print: 2021-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Ramakrishnan, Sanjay

Nicolau, Dan V Jr

Langford, Beverly

Mahdi, Mahdi

Jeffers, Helen

Mwasuku, Christine

Krassowska, Karolina

Fox, Robin

Binnian, Ian

Glover, Victoria

Bright, Stephen

Butler, Christopher

Cane, Jennifer L

Halner, Andreas

Matthews, Philippa C

Donnelly, Louise E

Simpson, Jodie L

Baker, Jonathan R

Fadai, Nabil T

Peterson, Stefan

Bengtsson, Thomas

Barnes, Peter J

Russell, Richard E K

Bafadhel, Mona
Funding

Funding for this research was provided by:

AstraZeneca PLC
License Information

Text and Data Mining valid from 2021-07-01

stm-asf valid from 2021-07-01

stm-asf valid from 2021-07-01

stm-asf valid from 2021-07-01

stm-asf valid from 2021-07-01

stm-asf valid from 2021-07-01
More Information

This article is maintained by: Elsevier

Article Title: Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Journal Title: The Lancet Respiratory Medicine

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S2213-2600(21)00160-0

CrossRef DOI link to the associated document: https://doi.org/10.1016/S2213-2600(21)00171-5

Content Type: article

Copyright: © 2021 Elsevier Ltd. All rights reserved.